Axena Health Accepted into AgeTech Collaborative™ from AARP Accelerator Program, Advancing Pelvic Health Solutions for Women 50+

Axena will leverage the program to support women facing menopause and age-related pelvic health conditions

NEWTON, Mass.--(BUSINESS WIRE)--Axena Health, Inc. (Axena Health), a medical device company redefining the standard of care for pelvic health conditions through clinically proven, non-invasive treatments, today announced it has been selected to participate in the AgeTech Collaborative™ from AARP Accelerator, an 8-week program designed to elevate promising AgeTech growth stage companies.

"We're thrilled to join the AgeTech Collaborative from AARP Accelerator program as we continue to improve the standard of care for women's pelvic health," said Randy Pritchard, CEO of Axena Health. "The mission aligns with our commitment to support all women experiencing bladder leakage, particularly as urinary incontinence becomes more common as women navigate the challenges of aging, especially after 50. Participation in the accelerator program, will be invaluable as we work to expand access to our clinically proven Leva Pelvic Health System and ensure more women receive the effective, first-line pelvic healthcare treatment they deserve."

Axena’s Leva® Pelvic Health System supports women experiencing bladder leakage (urinary incontinence) through a modern approach to pelvic floor muscle training (PFMT) – the recommended first-line treatment for urinary incontinence. Backed by 11 peer-reviewed studies, Leva’s 12-week comprehensive treatment program is clinically proven to reduce bladder leakage by up to 80 percent, with relief lasting for at least two years.

The AgeTech Collaborative™ from AARP Accelerator offers a customized 8-week program for next-generation innovators committed to making aging easier. Sourced through highly selective nationwide pitch events, top startups join the accelerator program by invitation, and they receive tailored support through AARP research, consumer feedback, subject matter expertise, growth marketing, and UI/UX consultation. The initiative focuses on championing meaningful technological advances that empower individuals to choose how they live as they age, making it an ideal program for Axena Health's mission to deliver clinically proven treatments that redefine the standard of care for women’s pelvic health.

In 2023, AARP highlighted the Leva Pelvic Health System as an advancement in women's health.

About Axena Health
Axena Health, Inc. is dedicated to improving the lives of women with pelvic floor disorders. Axena Health's flagship product, the Leva® Pelvic Health System, offers a novel, effective, first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI), underreported conditions affecting over 78 million and 12 million women in the U.S. alone. Axena Health's technology enables non-invasive, drug-free treatment via precise visualization of movement in real time during pelvic floor muscle training, while monitoring usage and progress. For more information, please visit www.axenahealth.com or www.levacares.com and follow Axena Health on LinkedIn.

About the Leva® Pelvic Health System
The Leva® Pelvic Health System offers an innovative, non-invasive, medication-free way for women to treat urinary incontinence (UI) and chronic fecal incontinence (FI) — at home in just five minutes a day. Combining a small FDA-cleared vaginal motion sensor with integrated software, the Leva System offers precise, real-time visualization of pelvic movement, progress tracking and active physician involvement, all of which support improved treatment outcomes. The Leva System is available by prescription only, enabling physician engagement in each patient’s success while also offering scalable first-line treatment of UI and chronic FI. The Leva System has multiple clinical trials and published data from globally recognized medical centers supporting its efficacy in treating UI, including two studies in Obstetrics and Gynecology (The Green Journal), the official publication of the American College of Obstetricians and Gynecologists (ACOG).

Important Indication and Other Information for the Leva® Pelvic Health System
The Leva® Pelvic Health System is intended for (1) strengthening of pelvic floor muscles, (2) rehabilitation and training of weak pelvic floor muscles for the treatment of stress, mixed, and mild to moderate urgency urinary incontinence (including overactive bladder) in women and (3) rehabilitation and training of weak pelvic floor muscles for the first-line treatment of chronic fecal incontinence (>3-month uncontrolled passage of feces) in women. Treatment with the Leva System is by prescription and is not for everyone. Please talk to your prescriber to see if Leva System is right for you. Your prescriber should discuss all potential benefits and risks with you. Do not use Leva System while pregnant, or if you think you may be pregnant, unless authorized by your doctor. For a complete summary of the risks and instructions for the Leva System, see its Instructions for Use available at www.levacares.com.